Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
United States
The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama Moffitt Cancer Center, Tampa, Florida The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox, Illinois UChicago Medicine Orland Park, Orland Park, Illinois University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota The University of Texas MD Anderson Cancer Center, Houston, Texas